Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NewAmsterdam Pharma (NAMS) Invested Capital (2022 - 2025)

NewAmsterdam Pharma's Invested Capital history spans 4 years, with the latest figure at $740.7 million for Q4 2025.

  • For Q4 2025, Invested Capital fell 6.83% year-over-year to $740.7 million; the TTM value through Dec 2025 reached $740.7 million, down 6.83%, while the annual FY2025 figure was $740.7 million, 6.83% down from the prior year.
  • Invested Capital for Q4 2025 was $740.7 million at NewAmsterdam Pharma, down from $772.4 million in the prior quarter.
  • Across five years, Invested Capital topped out at $800.9 million in Q1 2025 and bottomed at $301.0 million in Q4 2023.
  • The 4-year median for Invested Capital is $444.9 million (2024), against an average of $543.5 million.
  • The largest annual shift saw Invested Capital crashed 39.62% in 2023 before it surged 164.15% in 2024.
  • A 4-year view of Invested Capital shows it stood at $498.5 million in 2022, then plummeted by 39.62% to $301.0 million in 2023, then soared by 164.15% to $795.0 million in 2024, then decreased by 6.83% to $740.7 million in 2025.
  • Per Business Quant, the three most recent readings for NAMS's Invested Capital are $740.7 million (Q4 2025), $772.4 million (Q3 2025), and $799.4 million (Q2 2025).